| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 17 | 2022 | 611 | 2.940 |
Why?
|
| Liver Diseases | 6 | 2024 | 246 | 2.420 |
Why?
|
| Short Bowel Syndrome | 4 | 2024 | 38 | 2.410 |
Why?
|
| Capsule Endoscopy | 4 | 2023 | 33 | 2.380 |
Why?
|
| Parenteral Nutrition | 6 | 2024 | 62 | 2.240 |
Why?
|
| Colitis, Ulcerative | 13 | 2024 | 775 | 2.210 |
Why?
|
| Gastrointestinal Agents | 5 | 2024 | 179 | 1.650 |
Why?
|
| Gastroenterology | 3 | 2024 | 152 | 1.630 |
Why?
|
| Gastrointestinal Hemorrhage | 8 | 2023 | 244 | 1.390 |
Why?
|
| Liver | 4 | 2024 | 1228 | 1.320 |
Why?
|
| Nutrition Therapy | 2 | 2020 | 10 | 1.270 |
Why?
|
| Intestinal Diseases | 3 | 2020 | 80 | 1.260 |
Why?
|
| Crohn Disease | 9 | 2022 | 772 | 1.150 |
Why?
|
| Clostridium Infections | 6 | 2022 | 125 | 1.090 |
Why?
|
| Enteral Nutrition | 2 | 2024 | 103 | 1.060 |
Why?
|
| Humans | 91 | 2024 | 92337 | 1.040 |
Why?
|
| Autoimmune Diseases | 8 | 2021 | 252 | 1.040 |
Why?
|
| Neoplasms | 7 | 2024 | 3117 | 0.970 |
Why?
|
| Biosimilar Pharmaceuticals | 4 | 2020 | 25 | 0.970 |
Why?
|
| Endoscopy, Gastrointestinal | 3 | 2024 | 165 | 0.930 |
Why?
|
| Fish Oils | 1 | 2024 | 13 | 0.900 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2024 | 15 | 0.900 |
Why?
|
| Nutrition Assessment | 2 | 2021 | 20 | 0.870 |
Why?
|
| Rheumatic Diseases | 2 | 2021 | 28 | 0.860 |
Why?
|
| Hospitalization | 8 | 2023 | 927 | 0.850 |
Why?
|
| Infliximab | 4 | 2020 | 161 | 0.820 |
Why?
|
| Peptides | 2 | 2024 | 656 | 0.820 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2023 | 22 | 0.810 |
Why?
|
| Colitis | 3 | 2021 | 252 | 0.810 |
Why?
|
| Vaccination | 2 | 2022 | 285 | 0.800 |
Why?
|
| Retrospective Studies | 20 | 2024 | 9703 | 0.790 |
Why?
|
| Enterocolitis | 1 | 2022 | 13 | 0.790 |
Why?
|
| Opportunistic Infections | 1 | 2022 | 60 | 0.770 |
Why?
|
| Peritoneal Neoplasms | 2 | 2023 | 183 | 0.770 |
Why?
|
| Intestine, Small | 3 | 2023 | 301 | 0.760 |
Why?
|
| Cathartics | 1 | 2021 | 27 | 0.750 |
Why?
|
| Immune System Diseases | 2 | 2019 | 27 | 0.730 |
Why?
|
| Patient Readmission | 4 | 2024 | 393 | 0.730 |
Why?
|
| Enterocolitis, Pseudomembranous | 7 | 2015 | 52 | 0.720 |
Why?
|
| Vaccines | 1 | 2022 | 82 | 0.720 |
Why?
|
| Cytomegalovirus Infections | 1 | 2022 | 153 | 0.720 |
Why?
|
| Malnutrition | 1 | 2021 | 35 | 0.700 |
Why?
|
| Nasturtium | 1 | 2020 | 3 | 0.680 |
Why?
|
| Fasciola hepatica | 1 | 2020 | 4 | 0.680 |
Why?
|
| Antibodies, Helminth | 1 | 2020 | 10 | 0.680 |
Why?
|
| Fascioliasis | 1 | 2020 | 5 | 0.680 |
Why?
|
| Dyspepsia | 1 | 2020 | 9 | 0.680 |
Why?
|
| Angiodysplasia | 1 | 2019 | 4 | 0.660 |
Why?
|
| Neuroendocrine Tumors | 2 | 2019 | 131 | 0.650 |
Why?
|
| Spiders | 1 | 2019 | 17 | 0.650 |
Why?
|
| Eosinophilia | 1 | 2020 | 86 | 0.650 |
Why?
|
| Bone Resorption | 1 | 2019 | 45 | 0.640 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2019 | 36 | 0.620 |
Why?
|
| Risk Factors | 17 | 2024 | 5704 | 0.620 |
Why?
|
| Biological Products | 1 | 2021 | 171 | 0.620 |
Why?
|
| Intestinal Neoplasms | 1 | 2019 | 69 | 0.610 |
Why?
|
| Osteoporosis | 2 | 2019 | 124 | 0.610 |
Why?
|
| Central Venous Catheters | 1 | 2019 | 21 | 0.610 |
Why?
|
| Bariatric Surgery | 1 | 2021 | 206 | 0.610 |
Why?
|
| Organ Transplantation | 1 | 2022 | 288 | 0.610 |
Why?
|
| Organometallic Compounds | 1 | 2019 | 142 | 0.600 |
Why?
|
| Nutritional Sciences | 1 | 2018 | 13 | 0.580 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 498 | 0.570 |
Why?
|
| Gastroenterologists | 1 | 2018 | 32 | 0.560 |
Why?
|
| Osteogenesis | 1 | 2019 | 270 | 0.550 |
Why?
|
| Betacoronavirus | 1 | 2020 | 269 | 0.550 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2019 | 709 | 0.550 |
Why?
|
| Diet | 1 | 2020 | 448 | 0.540 |
Why?
|
| Intensive Care Units | 1 | 2020 | 429 | 0.530 |
Why?
|
| Female | 40 | 2024 | 47893 | 0.520 |
Why?
|
| Middle Aged | 27 | 2024 | 27030 | 0.520 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 130 | 0.510 |
Why?
|
| Mediastinal Diseases | 1 | 2016 | 22 | 0.510 |
Why?
|
| Male | 37 | 2024 | 43925 | 0.510 |
Why?
|
| Antibodies, Monoclonal | 7 | 2021 | 1399 | 0.510 |
Why?
|
| Celiac Disease | 1 | 2019 | 216 | 0.510 |
Why?
|
| Granuloma | 1 | 2016 | 64 | 0.510 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 328 | 0.480 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 313 | 0.480 |
Why?
|
| Deglutition Disorders | 1 | 2016 | 122 | 0.460 |
Why?
|
| Colonoscopy | 6 | 2024 | 300 | 0.460 |
Why?
|
| Aged | 19 | 2024 | 19943 | 0.460 |
Why?
|
| Adult | 24 | 2024 | 27532 | 0.450 |
Why?
|
| Ileitis | 1 | 2014 | 7 | 0.440 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 411 | 0.430 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2019 | 977 | 0.420 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2018 | 112 | 0.410 |
Why?
|
| Cystic Fibrosis | 3 | 2018 | 118 | 0.410 |
Why?
|
| Aspartate Aminotransferases | 2 | 2024 | 75 | 0.400 |
Why?
|
| Colorectal Neoplasms | 4 | 2023 | 1045 | 0.370 |
Why?
|
| Treatment Outcome | 17 | 2024 | 8740 | 0.360 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 1592 | 0.340 |
Why?
|
| Calcineurin Inhibitors | 2 | 2021 | 53 | 0.330 |
Why?
|
| Pharmaceutical Preparations | 2 | 2021 | 91 | 0.320 |
Why?
|
| Fibrosis | 2 | 2021 | 239 | 0.320 |
Why?
|
| Severity of Illness Index | 7 | 2021 | 1919 | 0.320 |
Why?
|
| Abdominal Pain | 2 | 2020 | 144 | 0.300 |
Why?
|
| Liver Cirrhosis | 3 | 2021 | 269 | 0.300 |
Why?
|
| Antirheumatic Agents | 2 | 2020 | 60 | 0.300 |
Why?
|
| Weight Loss | 3 | 2019 | 239 | 0.290 |
Why?
|
| Biopsy | 3 | 2021 | 1194 | 0.280 |
Why?
|
| Intubation, Gastrointestinal | 2 | 2024 | 31 | 0.280 |
Why?
|
| Mesentery | 2 | 2019 | 44 | 0.280 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2018 | 51 | 0.270 |
Why?
|
| Inpatients | 3 | 2021 | 331 | 0.270 |
Why?
|
| Gastrointestinal Diseases | 2 | 2017 | 153 | 0.240 |
Why?
|
| Colectomy | 2 | 2024 | 181 | 0.240 |
Why?
|
| Prospective Studies | 5 | 2021 | 4468 | 0.230 |
Why?
|
| Colitis, Microscopic | 1 | 2024 | 6 | 0.230 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2024 | 246 | 0.230 |
Why?
|
| Budesonide | 1 | 2024 | 46 | 0.220 |
Why?
|
| Alanine Transaminase | 1 | 2024 | 72 | 0.220 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2020 | 281 | 0.220 |
Why?
|
| Risk Assessment | 5 | 2019 | 2369 | 0.220 |
Why?
|
| Bilirubin | 1 | 2024 | 134 | 0.220 |
Why?
|
| Adenomatous Polyps | 1 | 2023 | 13 | 0.220 |
Why?
|
| Cohort Studies | 4 | 2024 | 2978 | 0.210 |
Why?
|
| Adolescent, Hospitalized | 1 | 2022 | 1 | 0.210 |
Why?
|
| Diarrhea | 2 | 2014 | 180 | 0.210 |
Why?
|
| Gastrostomy | 1 | 2023 | 68 | 0.200 |
Why?
|
| ROC Curve | 3 | 2021 | 785 | 0.200 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 58 | 0.200 |
Why?
|
| Ulcer | 1 | 2022 | 38 | 0.200 |
Why?
|
| Hemoglobins | 1 | 2023 | 190 | 0.200 |
Why?
|
| Diverticulum | 2 | 2019 | 44 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 2 | 2022 | 923 | 0.190 |
Why?
|
| Cytomegalovirus | 1 | 2022 | 85 | 0.190 |
Why?
|
| Adolescent | 11 | 2022 | 9504 | 0.190 |
Why?
|
| Young Adult | 10 | 2019 | 6624 | 0.180 |
Why?
|
| Platelet Count | 1 | 2021 | 92 | 0.180 |
Why?
|
| Hospitals | 1 | 2024 | 314 | 0.180 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2021 | 40 | 0.180 |
Why?
|
| Adenoma | 1 | 2023 | 255 | 0.180 |
Why?
|
| Double-Balloon Enteroscopy | 1 | 2021 | 11 | 0.180 |
Why?
|
| Gastrointestinal Tract | 1 | 2023 | 192 | 0.180 |
Why?
|
| Prognosis | 5 | 2022 | 3872 | 0.180 |
Why?
|
| Nutritional Status | 1 | 2021 | 82 | 0.180 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 302 | 0.170 |
Why?
|
| Propensity Score | 1 | 2021 | 165 | 0.170 |
Why?
|
| Societies, Medical | 1 | 2024 | 601 | 0.170 |
Why?
|
| Vitamin D | 2 | 2021 | 269 | 0.170 |
Why?
|
| Antiplatyhelmintic Agents | 1 | 2020 | 5 | 0.170 |
Why?
|
| Life Cycle Stages | 1 | 2020 | 15 | 0.170 |
Why?
|
| Biomarkers | 4 | 2021 | 1850 | 0.170 |
Why?
|
| Interleukin-23 | 1 | 2020 | 57 | 0.170 |
Why?
|
| Colonic Polyps | 1 | 2021 | 134 | 0.170 |
Why?
|
| Warfarin | 1 | 2020 | 105 | 0.170 |
Why?
|
| Lubricants | 1 | 2019 | 7 | 0.160 |
Why?
|
| Laxatives | 1 | 2019 | 13 | 0.160 |
Why?
|
| Panniculitis, Peritoneal | 1 | 2019 | 4 | 0.160 |
Why?
|
| Aged, 80 and over | 7 | 2023 | 6916 | 0.160 |
Why?
|
| Double-Blind Method | 1 | 2024 | 1756 | 0.160 |
Why?
|
| Interleukin-12 | 1 | 2020 | 111 | 0.160 |
Why?
|
| Vitamin D Deficiency | 1 | 2021 | 105 | 0.160 |
Why?
|
| Cyclosporine | 2 | 2018 | 241 | 0.160 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2019 | 19 | 0.160 |
Why?
|
| Prevalence | 5 | 2021 | 1294 | 0.160 |
Why?
|
| Travel | 1 | 2020 | 72 | 0.160 |
Why?
|
| Mesenteric Veins | 1 | 2019 | 34 | 0.160 |
Why?
|
| Respiratory Tract Infections | 1 | 2020 | 111 | 0.160 |
Why?
|
| Drug Substitution | 1 | 2019 | 27 | 0.160 |
Why?
|
| Tacrolimus | 2 | 2018 | 373 | 0.160 |
Why?
|
| Radionuclide Imaging | 1 | 2019 | 217 | 0.160 |
Why?
|
| Logistic Models | 3 | 2018 | 1239 | 0.150 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2020 | 178 | 0.150 |
Why?
|
| Diet, Gluten-Free | 1 | 2019 | 59 | 0.150 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2019 | 69 | 0.150 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2020 | 137 | 0.150 |
Why?
|
| Odds Ratio | 6 | 2017 | 694 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2018 | 205 | 0.150 |
Why?
|
| Interleukin-17 | 1 | 2019 | 107 | 0.150 |
Why?
|
| Ileum | 1 | 2019 | 168 | 0.150 |
Why?
|
| Osteoporotic Fractures | 1 | 2019 | 51 | 0.150 |
Why?
|
| Ribotyping | 2 | 2015 | 11 | 0.150 |
Why?
|
| Incidence | 5 | 2021 | 1661 | 0.140 |
Why?
|
| Bone Density | 1 | 2019 | 226 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 278 | 0.140 |
Why?
|
| Survival Rate | 1 | 2022 | 1927 | 0.140 |
Why?
|
| Equipment Design | 1 | 2019 | 418 | 0.140 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2017 | 16 | 0.140 |
Why?
|
| Fractures, Bone | 1 | 2019 | 146 | 0.140 |
Why?
|
| Pandemics | 2 | 2020 | 812 | 0.140 |
Why?
|
| United States | 4 | 2024 | 7348 | 0.140 |
Why?
|
| CTLA-4 Antigen | 1 | 2017 | 141 | 0.140 |
Why?
|
| Carcinoma, Small Cell | 1 | 2017 | 136 | 0.130 |
Why?
|
| Glucocorticoids | 2 | 2020 | 367 | 0.130 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 469 | 0.130 |
Why?
|
| Itraconazole | 1 | 2016 | 11 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 1763 | 0.130 |
Why?
|
| Ambulatory Care | 1 | 2018 | 195 | 0.130 |
Why?
|
| Paracentesis | 1 | 2016 | 9 | 0.130 |
Why?
|
| Ascites | 1 | 2016 | 57 | 0.130 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 807 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 183 | 0.130 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 377 | 0.120 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2017 | 119 | 0.120 |
Why?
|
| Endoscopy | 1 | 2019 | 363 | 0.120 |
Why?
|
| Bronchoscopy | 1 | 2017 | 167 | 0.120 |
Why?
|
| Lymph Nodes | 1 | 2019 | 552 | 0.120 |
Why?
|
| Wound Healing | 1 | 2018 | 373 | 0.120 |
Why?
|
| Antifungal Agents | 1 | 2016 | 125 | 0.120 |
Why?
|
| Age Factors | 5 | 2018 | 1905 | 0.120 |
Why?
|
| Women's Health | 1 | 2016 | 105 | 0.120 |
Why?
|
| Botulinum Toxins | 1 | 2015 | 17 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 237 | 0.120 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 472 | 0.120 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 215 | 0.120 |
Why?
|
| Pregnancy Outcome | 1 | 2016 | 265 | 0.120 |
Why?
|
| Registries | 1 | 2020 | 902 | 0.120 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2014 | 23 | 0.110 |
Why?
|
| Remission Induction | 3 | 2024 | 763 | 0.110 |
Why?
|
| Intestinal Obstruction | 1 | 2015 | 91 | 0.110 |
Why?
|
| Calcium | 1 | 2019 | 1183 | 0.110 |
Why?
|
| History, 18th Century | 1 | 2014 | 21 | 0.110 |
Why?
|
| History, 19th Century | 1 | 2014 | 57 | 0.110 |
Why?
|
| Pregnancy Complications | 1 | 2016 | 346 | 0.110 |
Why?
|
| Erythrocyte Transfusion | 1 | 2014 | 69 | 0.100 |
Why?
|
| Calcitonin | 1 | 2013 | 39 | 0.100 |
Why?
|
| Curriculum | 1 | 2018 | 581 | 0.100 |
Why?
|
| Feces | 1 | 2015 | 349 | 0.100 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 120 | 0.100 |
Why?
|
| Frail Elderly | 1 | 2013 | 85 | 0.100 |
Why?
|
| Animals | 4 | 2020 | 28003 | 0.100 |
Why?
|
| Protein Precursors | 1 | 2013 | 138 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2016 | 362 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2014 | 317 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 1398 | 0.100 |
Why?
|
| Kidney Transplantation | 1 | 2018 | 863 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2017 | 725 | 0.090 |
Why?
|
| Motor Activity | 1 | 2013 | 330 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 887 | 0.090 |
Why?
|
| Child | 6 | 2022 | 7334 | 0.090 |
Why?
|
| Postoperative Period | 2 | 2021 | 311 | 0.080 |
Why?
|
| CD40 Antigens | 1 | 2009 | 44 | 0.080 |
Why?
|
| Liver Transplantation | 1 | 2016 | 1186 | 0.080 |
Why?
|
| Length of Stay | 3 | 2021 | 798 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 2680 | 0.080 |
Why?
|
| Interleukin-2 | 1 | 2009 | 245 | 0.080 |
Why?
|
| Liver Function Tests | 2 | 2020 | 93 | 0.080 |
Why?
|
| Recurrence | 3 | 2021 | 1180 | 0.080 |
Why?
|
| Databases, Factual | 3 | 2019 | 955 | 0.080 |
Why?
|
| Time Factors | 4 | 2018 | 5430 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1720 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 3509 | 0.070 |
Why?
|
| Antibodies | 1 | 2009 | 351 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 1277 | 0.070 |
Why?
|
| Interleukin-6 | 2 | 2020 | 272 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 2394 | 0.060 |
Why?
|
| Colitis, Collagenous | 1 | 2024 | 2 | 0.060 |
Why?
|
| Colitis, Lymphocytic | 1 | 2024 | 4 | 0.060 |
Why?
|
| Proton Pump Inhibitors | 1 | 2024 | 34 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2018 | 3818 | 0.050 |
Why?
|
| Michigan | 2 | 2013 | 53 | 0.050 |
Why?
|
| Disease Progression | 2 | 2018 | 1503 | 0.050 |
Why?
|
| Hospital Mortality | 2 | 2016 | 444 | 0.050 |
Why?
|
| Piperidines | 1 | 2022 | 164 | 0.050 |
Why?
|
| Pregnancy | 2 | 2020 | 3110 | 0.050 |
Why?
|
| Diverticulum, Esophageal | 1 | 1981 | 6 | 0.040 |
Why?
|
| Dabigatran | 1 | 2020 | 25 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2021 | 85 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 82 | 0.040 |
Why?
|
| Morphinans | 1 | 2019 | 4 | 0.040 |
Why?
|
| Cholestasis | 1 | 2020 | 43 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 2020 | 74 | 0.040 |
Why?
|
| Steroids | 1 | 2020 | 173 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 673 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 375 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 661 | 0.040 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2019 | 64 | 0.040 |
Why?
|
| Dermatologic Agents | 1 | 2019 | 75 | 0.040 |
Why?
|
| Naltrexone | 1 | 2019 | 139 | 0.040 |
Why?
|
| Spinal Fractures | 1 | 2019 | 95 | 0.040 |
Why?
|
| Narcotic Antagonists | 1 | 2019 | 165 | 0.040 |
Why?
|
| Life Expectancy | 1 | 2018 | 89 | 0.040 |
Why?
|
| Biological Therapy | 1 | 2018 | 47 | 0.040 |
Why?
|
| Age Distribution | 1 | 2018 | 206 | 0.040 |
Why?
|
| Databases, Bibliographic | 1 | 2017 | 17 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 361 | 0.030 |
Why?
|
| Data Mining | 1 | 2017 | 44 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2020 | 443 | 0.030 |
Why?
|
| Hepatitis, Chronic | 1 | 2016 | 5 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 205 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 866 | 0.030 |
Why?
|
| Colon | 1 | 2020 | 527 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2017 | 151 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 989 | 0.030 |
Why?
|
| Infant | 2 | 2014 | 3218 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 868 | 0.030 |
Why?
|
| Directive Counseling | 1 | 2016 | 35 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2019 | 339 | 0.030 |
Why?
|
| Cost Savings | 1 | 2016 | 72 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 97 | 0.030 |
Why?
|
| Vomiting | 1 | 2017 | 199 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 214 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 996 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2016 | 115 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1095 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2020 | 814 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 810 | 0.030 |
Why?
|
| Patient Safety | 1 | 2017 | 221 | 0.030 |
Why?
|
| Cladribine | 1 | 2014 | 35 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 299 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 446 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2020 | 2087 | 0.030 |
Why?
|
| Phytohemagglutinins | 1 | 2014 | 21 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 152 | 0.030 |
Why?
|
| Antigens, CD1 | 1 | 2014 | 37 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2014 | 136 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 351 | 0.030 |
Why?
|
| Blood Preservation | 1 | 2014 | 11 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 85 | 0.030 |
Why?
|
| CD28 Antigens | 1 | 2014 | 93 | 0.030 |
Why?
|
| Gastroenteritis | 1 | 2014 | 26 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2014 | 235 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2014 | 476 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2020 | 2517 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 154 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2016 | 963 | 0.030 |
Why?
|
| Lung Transplantation | 1 | 2018 | 350 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 490 | 0.030 |
Why?
|
| Chicago | 1 | 2018 | 1466 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 219 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 162 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 531 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2014 | 172 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 187 | 0.030 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2013 | 40 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 390 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2014 | 301 | 0.030 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 556 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 341 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 3360 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2015 | 578 | 0.020 |
Why?
|
| Mice | 2 | 2020 | 12110 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2004 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2014 | 438 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2021 | 2458 | 0.020 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2009 | 10 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2009 | 16 | 0.020 |
Why?
|
| Chemokine CXCL9 | 1 | 2009 | 7 | 0.020 |
Why?
|
| Receptors, Cytokine | 1 | 2009 | 29 | 0.020 |
Why?
|
| Arginase | 1 | 2009 | 16 | 0.020 |
Why?
|
| Receptors, CCR2 | 1 | 2009 | 33 | 0.020 |
Why?
|
| Chemokines, CC | 1 | 2009 | 37 | 0.020 |
Why?
|
| Chemokines | 1 | 2009 | 74 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1902 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 312 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2014 | 2902 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2020 | 3508 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2009 | 149 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2009 | 1108 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 1774 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2009 | 461 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 3775 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 2794 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2009 | 624 | 0.020 |
Why?
|
| Mutation | 1 | 2014 | 4204 | 0.010 |
Why?
|